Drug sensitivity analysis for high and low risk subtypes showed that pancreatic cancer had a lower IC50 value for PI3K/Akt/mTOR signal transduction pathway inhibitors Buparlisib, Rapamycinm, AZD8055, AZD2014, and AZD6482 (Fig. 8a). Here, MTOR is linked to familial pancreatic carcinoma.